Article By:
Lorimer Wilson
Sunday, December 12, 2021 11:46 AM EDT
The six marijuana-based clinical-stage stocks are down 31.1% since the end of June; the 9 psychedelic compound-based clinical-stage stocks with market caps under $1B are down 36.3% in that same timeframe.